Response to pneumococcal polysaccharide vaccination in healthy adults

Recruiting

• Conditions: specific antibody deficiency; immunodeficiency; 10021460

• Registration Number: NL-OMON55592
• Lead Sponsor: Sint Antonius Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 210

Inclusion Criteria

• Age >=18 years and <=80 years
• Fits within pre-specified age and gender stratification blocks
• Informed consent

Exclusion Criteria

• Previous vaccination with pneumococcal polysaccharide or conjugate vaccination
• Chronic disease that requires the use of immunosuppressive agents
• Known or highly suspected primary or secondary immunodeficiency
• Pregnancy
• Fever or active infection
• History of allergic reaction to one of the vaccine components

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Distribution of serotype-specific IgG antibody titers to 13 pneumococcal<br /><br>serotypes four weeks after vaccination.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Distribution of serotype-specific IgG antibody titers to 13 pneumococcal<br /><br>serotypes eight weeks after vaccination.<br /><br>Distribution of serotype-specific IgG1, IgG2, IgM and IgA antibody titers to 13<br /><br>pneumococcal serotypes four and eight weeks after vaccination.<br /><br>Distribution of serotype-specific percent change in IgG, IgG1, IgG2, IgM and<br /><br>IgA antibody titers to 13 pneumococcal serotypes four and eight weeks after<br /><br>vaccination in comparison to pre-vaccination.</p><br>